Why the study?
It was unclear whether VT non-inducibility should be used as a routine endpoint in VT ablation, prompting evaluation of recurrence and its predictors when non-inducibility is not achieved.
What are the predictors of VT recurrence in patients with VT inducibility at the end of radiofrequency ablation?
What are the predictors of VT recurrence in patients with VT inducibility at the end of radiofrequency ablation?
In patients with inducible VT after ablation, LVEF ≥35% and successful ablation of all clinical VT isthmuses predict lower VT recurrence, suggesting non-inducibility may not be a mandatory endpoint for all patients.
VT non-inducibility may not be mandatory post-ablation; leaves open optimal endpoints and predictors of recurrence in structural heart disease.
Introduction: It has been reported that ventricular tachycardia (VT) non-inducibility at the end of ablation is associated with less likely VT recurrence. However, it is not clear whether we should use VT non-inducibility as routine end point in VT ablation. The aim of this study was to evaluate VT recurrence in patients in whom VT non-inducibility could not be achieved at the end of the RF ablation and the factors attributing to the VT recurrence. METHODS and RESULTS: We analyzed 84 consecutive patients that underwent RF ablation, and 64 patients in whom VT non-inducibility could not be achieved were studied. The primary endpoint was recurrence of any sustained VT during the follow-up. During a median follow-up period of 1.4 years (IQR:0.3-2.0), 22 (34%) of the cases had VT recurrences. In the multivariate analysis showed that an LVEF≥35% (HR:0.21; 95% CI:0.07- 0.54; P<0.01) and successful identification and ablation of all clinical VT isthmuses (HR:0.21; 95% CI:0.03- 0.72; P=0.01) were independent predictors of fewer VT recurrences. RF ablation was associated with a 91.1% reduction in VT episodes. CONCLUSION: Even if VT non-inducibility could not be achieved, the patients with LVEF≥35% or in whom all clinical VT isthmuses could successfully be identify and ablated might be prevented from having VT recurrences. The validity of VT non-inducibility of any VT should be evaluated by each patient’s background and the results of the procedure.
No takes yet. Share an insight, caveat, or question.
Nakasone et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: